X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (439) 439
Publication (75) 75
Book Chapter (6) 6
Book Review (6) 6
Newsletter (6) 6
Newspaper Article (2) 2
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
darunavir (363) 363
humans (321) 321
index medicus (267) 267
hiv infections - drug therapy (226) 226
pharmacology & pharmacy (191) 191
male (181) 181
female (169) 169
pharmacokinetics (168) 168
hiv (162) 162
infectious diseases (161) 161
ritonavir (150) 150
adult (148) 148
middle aged (143) 143
sulfonamides - pharmacokinetics (108) 108
protease inhibitors (100) 100
ritonavir - administration & dosage (100) 100
safety (100) 100
drug interactions (99) 99
sulfonamides - administration & dosage (99) 99
drug therapy, combination (96) 96
efficacy (96) 96
ritonavir - pharmacokinetics (93) 93
hiv protease inhibitors - pharmacokinetics (91) 91
antiretroviral therapy (87) 87
hiv protease inhibitors - therapeutic use (85) 85
antiviral agents (83) 83
anti-hiv agents - administration & dosage (82) 82
anti-hiv agents - pharmacokinetics (82) 82
hiv protease inhibitors - administration & dosage (78) 78
immunology (78) 78
sulfonamides - therapeutic use (73) 73
microbiology (71) 71
hiv-1 - drug effects (69) 69
hiv infection (68) 68
ritonavir - therapeutic use (68) 68
treatment outcome (68) 68
drug therapy (65) 65
antiretroviral drugs (61) 61
human immunodeficiency virus--hiv (61) 61
anti-hiv agents - therapeutic use (60) 60
hiv infections - virology (60) 60
young adult (59) 59
virology (55) 55
atazanavir (53) 53
protease inhibitor (53) 53
lopinavir (51) 51
hiv protease inhibitors - adverse effects (50) 50
viral load (50) 50
adolescent (49) 49
dosage and administration (49) 49
darunavir/ritonavir (48) 48
hiv-1 (47) 47
darunavir - pharmacokinetics (46) 46
highly active antiretroviral therapy (46) 46
research (46) 46
etravirine (45) 45
hiv protease inhibitors - pharmacology (44) 44
raltegravir (44) 44
sulfonamides - adverse effects (44) 44
animals (43) 43
sulfonamides - pharmacology (40) 40
pharmacology (39) 39
therapy (39) 39
drug resistance, viral (38) 38
aids/hiv (37) 37
darunavir - therapeutic use (37) 37
hiv protease inhibitors - blood (37) 37
hiv-1-infected patients (37) 37
sulfonamides - blood (37) 37
darunavir - administration & dosage (36) 36
plasma (36) 36
aged (35) 35
cobicistat (35) 35
health aspects (35) 35
tenofovir (35) 35
analysis (33) 33
treatment-naive (32) 32
anti-hiv agents - adverse effects (31) 31
antiretroviral agents (31) 31
double-blind (31) 31
drugs (31) 31
efavirenz (31) 31
hiv infections - metabolism (31) 31
hiv-infected patients (31) 31
infection (31) 31
ritonavir - adverse effects (31) 31
ritonavir - blood (31) 31
ritonavir - pharmacology (31) 31
virus diseases (31) 31
drug administration schedule (30) 30
drug combinations (30) 30
drug resistance (30) 30
tmc114 (30) 30
hiv infections - blood (29) 29
p-glycoprotein (29) 29
pregnancy (29) 29
proteases (29) 29
treatment-experienced patients (29) 29
aids (28) 28
emtricitabine (28) 28
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 3/2013, Volume 56, Issue 5, pp. 718 - 726
Journal Article
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 2/2012, Volume 54, Issue 3, pp. 414 - 423
Background. This study examined drug interactions between buprenorphine, a partial opioid agonist used for opioid dependence treatment and pain management, and... 
Statistical median | HIV/AIDS | HIV | Memory interference | Drug interactions | Medications | Methadone | Pharmacokinetics | Dosage | Data ranges | Opioid analgesics | INFECTIOUS DISEASES | GLUCURONIDATION | VALIDATION | MICROBIOLOGY | OPIOID DEPENDENCE | DARUNAVIR/RITONAVIR | OPIATE WITHDRAWAL | IMMUNOLOGY | DRUG-DRUG INTERACTION | NORBUPRENORPHINE | PHARMACOKINETICS | METHADONE | IN-VIVO | History, 17th Century | Narcotic Antagonists - administration & dosage | Darunavir | Area Under Curve | Buprenorphine - blood | Protease Inhibitors - pharmacokinetics | Humans | Half-Life | Buprenorphine - pharmacokinetics | Male | Carbamates - administration & dosage | Carbamates - pharmacokinetics | Anti-HIV Agents - administration & dosage | Sulfonamides - blood | Drug Interactions | Buprenorphine - analogs & derivatives | Protease Inhibitors - administration & dosage | Female | Opiate Substitution Treatment | Anti-HIV Agents - blood | Narcotic Antagonists - pharmacokinetics | Organophosphates - administration & dosage | Organophosphates - pharmacokinetics | Ritonavir - administration & dosage | Organophosphates - blood | Ritonavir - blood | History, 16th Century | Carbamates - blood | Sulfonamides - pharmacokinetics | Buprenorphine - administration & dosage | Ritonavir - pharmacokinetics | Naloxone - pharmacology | Anti-HIV Agents - pharmacokinetics | Protease Inhibitors - blood | Sulfonamides - administration & dosage | Usage | Fosamprenavir | Dosage and administration | Buprenorphine | Protease inhibitors | AIDS
Journal Article
Journal Article
Journal Article
Frontiers in Pharmacology, ISSN 1663-9812, 08/2016, Volume 7, Issue AUG
markdownabstract__Background__ The study goal was to describe etravirine pharmacokinetics during pregnancy and postpartum in HIV-infected women. __Methods__... 
Pregnancy | HIV | Perinatal transmission | Pharmacokinetics | Etravirine | DARUNAVIR | RALTEGRAVIR | EFFICACY | SAFETY | pregnancy | etravirine | DARUNAVIR/RITONAVIR | PHARMACODYNAMICS | COMBINATION | WOMAN | ENFUVIRTIDE | pharmacokinetics | PHARMACOLOGY & PHARMACY | perinatal transmission | TRANSPLACENTAL PASSAGE | Pregnant women | Physiological aspects | HIV patients | Dosage and administration | Observations | Health aspects
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 02/2017, Volume 61, Issue 2
The three-direct-acting antiviral (3D) regimen containing ombitasvir, paritaprevir, ritonavir, and dasabuvir with or without ribavirin (RBV) is approved for... 
Ombitasvir | Darunavir | HIV | DAA | HCV | Paritaprevir | Dasabuvir | EFFICACY | ombitasvir | SAFETY | MICROBIOLOGY | OPEN-LABEL | paritaprevir | PHARMACOLOGY & PHARMACY | darunavir | AGENTS | PARITAPREVIR/RITONAVIR | dasabuvir | Anilides - therapeutic use | Darunavir - pharmacokinetics | Antiviral Agents - pharmacokinetics | Hepatitis C - drug therapy | Hepatitis C - metabolism | Coinfection - drug therapy | Humans | Middle Aged | Male | Anilides - pharmacokinetics | Carbamates - administration & dosage | Carbamates - pharmacokinetics | Uracil - administration & dosage | Darunavir - administration & dosage | Ritonavir - therapeutic use | Adult | Female | Drug Administration Schedule | Ritonavir - administration & dosage | Antiviral Agents - therapeutic use | Macrocyclic Compounds - pharmacokinetics | Uracil - therapeutic use | Coinfection - metabolism | Antiviral Agents - administration & dosage | Sulfonamides - pharmacokinetics | Macrocyclic Compounds - therapeutic use | Ritonavir - pharmacokinetics | Anilides - administration & dosage | Sulfonamides - therapeutic use | HIV Infections - drug therapy | Aged | Macrocyclic Compounds - administration & dosage | Carbamates - therapeutic use | Uracil - pharmacokinetics | Darunavir - therapeutic use | Sulfonamides - administration & dosage | HIV Infections - metabolism | Uracil - analogs & derivatives
Journal Article
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 08/2014, Volume 54, Issue 8, pp. 949 - 957
This study compared the bioavailability of two candidate fixed‐dose combinations (FDCs: G003 and G004) of darunavir/cobicistat 800/150 mg with that of... 
fixed‐dose combination | darunavir | cobicistat | bioavailability | pharmacoenhancer | fixed-dose combination | EFFICACY | SAFETY | HIV-1-INFECTED PATIENTS | ANTIRETROVIRAL THERAPY | PROTEASE INHIBITORS | TREATMENT-NAIVE | HIV | TREATMENT-EXPERIENCED PATIENTS | PHARMACOLOGY & PHARMACY | LOPINAVIR/RITONAVIR | ONCE-DAILY DARUNAVIR/RITONAVIR | Thiazoles - blood | Darunavir | Humans | Middle Aged | Biological Availability | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Healthy Volunteers | Carbamates - pharmacokinetics | Thiazoles - adverse effects | Thiazoles - pharmacokinetics | Young Adult | Sulfonamides - blood | Ritonavir - adverse effects | HIV Protease Inhibitors - pharmacokinetics | Adult | Female | HIV Protease Inhibitors - adverse effects | HIV Protease Inhibitors - blood | Cytochrome P-450 CYP3A Inhibitors - administration & dosage | Cytochrome P-450 CYP3A Inhibitors - blood | Ritonavir - administration & dosage | Ritonavir - blood | Carbamates - blood | HIV Protease Inhibitors - administration & dosage | Sulfonamides - pharmacokinetics | Cross-Over Studies | Ritonavir - pharmacokinetics | Sulfonamides - adverse effects | Carbamates - adverse effects | Cytochrome P-450 CYP3A Inhibitors - adverse effects | Cobicistat | Drug Combinations | Sulfonamides - administration & dosage | Usage | Dosage and administration | Drug therapy, Combination | Pharmacokinetics | Analysis | Short term
Journal Article